Key result
In normotensive patients with type 2 diabetes, SGLT2 inhibitor treatment changed the circadian blood pressure pattern from nondipper to dipper in 17.9% of patients, with no significant difference between dapagliflozin and empagliflozin.
Why the study?
The study aimed to investigate the effect of SGLT2 inhibitors on circadian blood pressure rhythm in normotensive patients with type 2 DM not taking antihypertensives.
Do SGLT2 inhibitors improve circadian blood pressure rhythm in normotensive patients with type 2 diabetes mellitus?
Observational (n=67)
Open-label
1:1
No
Do SGLT2 inhibitors improve circadian blood pressure rhythm in normotensive patients with type 2 diabetes mellitus?
SGLT2 inhibitors may favorably alter circadian blood pressure patterns from nondipper to dipper in normotensive patients with type 2 diabetes.
May affect circadian BP rhythm in normotensive T2DM; hypothesis-generating and leaves open need for randomized confirmation.
Introduction: Introduction: The aim of this study was to investigate the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on circadian blood pressure rhythm in normotensive patients diagnosed with type 2 diabetes mellitus (DM) who were not on antihypertensives.Methods: Methods: The study included normotensive patients with type 2 DM who were initiated on SGLT2 inhibitors (empagliflozin, n=31; dapagliflozin, n=36) in addition to an antihyperglycemic agent.Results: Results: Systolic blood pressure (SBP) and diastolic blood pressure (DBP) changed from a nondipper to a dipper pattern after treatment in 22.4% (n=15) and 25.4% (n=17) of the patients, respectively.Both SBP and DBP changed from a nondipper to a dipper pattern after treatment in 17.9% (n=12) of all patients.This change in circadian blood pressure was not significantly different for the dapagliflozin and empagliflozin groups (p>0.05).Fasting blood sugar and HbA1c levels significantly decreased in both groups after SGLT2 inhibitor treatment (p<0.001).Serum creatinine and spot urine microalbumin levels and the microalbumin/creatinine ratio decreased significantly in both groups (p<0.05).The posttreatment decrease in spot urine protein and creatinine levels was significantly higher in the dapagliflozin group compared to the empagliflozin group (p<0.05). Conclusion: Conclusion:The circadian blood pressure pattern changed from a dipper to a nondipper pattern in normotensive type 2 DM patients after they used SGLT2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Karahan et al. (2023) conducted an observational in Type 2 Diabetes Mellitus (n=67). SGLT2 inhibitors (dapagliflozin or empagliflozin) vs. Baseline was evaluated on Change in circadian blood pressure from a nondipper to a dipper pattern (p=>0.05). In normotensive patients with type 2 diabetes, SGLT2 inhibitor treatment changed the circadian blood pressure pattern from nondipper to dipper in 17.9% of patients, with no significant difference between dapagliflozin and empagliflozin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: